Updated Screening Guidelines for 5 Cancer Types clinicaladvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaladvisor.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton,.
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Search jobs 05-May-2021 Latest Study on Cervical Cancer Diagnostic Tests Market 2021 | Global Industry Size, Hinder Growth, Global Trend, Revenue, Manufacturers are DYSIS Medical Ltd., Abbott Laboratories, Becton, Dickinson and Company, The Cooper Companies, Inc., Danaher Corporation
SEATTLE, May 05, 2021, (PHARMIWEB)
Global Cervical Cancer Diagnostic Tests Market, By Test Type (Pap Smear Test, Colposcopy Test, ECC Test, and HPV Test), By Age Group (Age 20 – 40 and Age Above 40), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 5,910.2 million in 2020 and is estimated to register a CAGR over 6.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Journal of Lower Genital Tract Disease publishes a clinical trial endorsing PAPILOCARE as a proven treatment that prevents and treats lesions caused by HPV
of patients affected by high-risk HPV
The Paloma Clinical trial also certifies a clearance of HPV in 63% of patients with high-risk HPV treated with PAPILOCARE compared with 40% in the control group.
MADRID, Spain, April 7, 2021 /PRNewswire/
The
Journal of Lower Genital Tract Disease (JLGTD), the official journal of the American Society for Colposcopy and Cervical Pathology (ASCCP),
have published the final results of the Paloma Clinical Trial, which demonstrated the efficacy of PAPILOCARE in preventing and treating lesions caused by HPV. Its main conclusions include the